Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes Read More »
“Employers, unions, and state health programs hire pharmacy benefit managers (PBMs) to reduce costs for patients by, among other things, negotiating discounts with drug companies and drugstores. Read More »
Sanofi (NYSE: SNY; EURONEXT: SAN) and Regeneron Pharmaceuticals, Inc. today announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts. Read More »
Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). Read More »
Officially approved for leukemia treatment by the FDA just one month ago, Pfizer Inc.’s BESPONSA has gained a primary distributor to provide the drug to pharmacies across the U.S. Read More »
A generic formulation of AstraZeneca’s Nexium medication that delivers time-released doses of the drug to aid acid-reflux sufferers has received FDA approval and should soon be available for purchase. Read More »
The Rite Aid Foundation recently announced the rollout of its KidCents Safe Medication Disposal Program, which will focus on reducing drug accessibility, medication misuse and accidental poisoning of children and adolescents. Read More »
Novartis recently announced that the U.S. Food and Drug Administration (FDA) approved Kymriah suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Read More »
Coherus BioSciences Inc. of Redwood City, California recently announced initial results from several current clinical pharmacokinetic bioequivalence (PK/BE) studies comparing two products, both developed for the purpose of addressing certain chronic arthritic and skin conditions. Read More »
Endo International plc of Dublin, Ireland recently launched shipping operations for its generic Sabril (vigabatrin for oral solution USP, 500 mg) product via Par Pharmaceutical, following final approval of its Abbreviated New Drug Application (ANDA). Read More »
Orfadin, a drug used to treat a condition causing kidney and liver damage, has now received the FDA’s go-ahead for once-a-day use, cutting its dosing frequency in half. Read More »
Albertsons Cos. plans on continued care for its customers as flu season approaches, reporting from its Boise, Idaho base that influenza vaccines are now in stock. Read More »
Drug developer Ligand Pharmaceuticals Inc. (LGND) of San Diego, California will receive $2 million plus royalties and other benefits from WuXi Biologics in a new licensing agreement involving an antibody technology, company officials announced recently. Read More »
Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More »
Avella Specialty Pharmacy has been recognized by Inc. Magazine as one of the 5,000 fastest-growing companies in the United States. Read More »
Walgreens has been awarded the 2017 Infinity Arrow Award for Service and Take Back by the California Product Stewardship Council (CPSC) in recognition of the company’s Safe Medication Disposal program. Read More »
Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members. Read More »
After a comprehensive review, CVS Pharmacy has retained Community Pharmacy Accreditation from industry benchmark organization Utilization Review Accreditation Commission. Read More »
Takeda Pharmaceuticals Co. Limited recently announced that it will collaborate with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM) to transform novel Stanford research into next-generation treatments for diseases. Read More »
Ionis Pharmaceuticals Inc. will retain all rights to inotersen and IONIS-FB-LRx. Read More »
Alerts Sign-up
